C9 and amyotrophic lateral sclerosis: Therefore, molecular therapies directed at nucleic acid structures formed in the C9-NRE mutation DNA region are a promising therapeutic target for mitigating pathological hallmarks of C9-NRE-linked ALS/FTD disease in vitro and in vivo.